Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Damora Therapeutics, Inc.GLTO · Entity 4602 | Chief Financial Officer | January 03, 2024 | January 05, 2024 |
| F-star Therapeutics, Inc.SBPH · Entity 115726 | CFO & Treasurer | March 05, 2020 | March 09, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Damora Therapeutics, Inc.
Report date January 03, 2024 · Filed January 05, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 100,000 |
Reported balance
After 2024-01-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-01-03 · Grant · Acquired 100,000 · Balance 100,000 F1: Each restricted stock unit represents the right to receive, at settlement, one share of common stock of Galecto, Inc. One-third of the restricted stock units subject to the award will vest on January 3, 2025 and the remaining restricted stock units will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the right to receive, at settlement, one share of common stock of Galecto, Inc. One-third of the restricted stock units subject to the award will vest on January 3, 2025 and the remaining restricted stock units will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date.
F-star Therapeutics, Inc.
Report date March 05, 2020 · Filed March 09, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.41 · Expires 2030-03-04 | Direct | 25,000 |
Reported balance
After 2020-03-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-03-05 · Grant · Acquired 25,000 · Balance 25,000 F1: This option was granted on March 5, 2020, with 25% of the shares subject to the option vesting on March 5, 2021 and the remaining 75% of the shares subject to the option vesting in 36 equal monthly installments thereafter. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 25,000 |
Reported balance
After 2020-03-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-03-05 · Grant · Acquired 25,000 · Balance 25,000 F2: Each restricted stock unit represents a contingent right to receive one share of Spring Bank Pharmaceuticals, Inc. common stock. F3: The restricted stock units will vest in two installments. Fifty percent will vest on March 5, 2021 and the remaining fifty percent will vest on December 31, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on March 5, 2020, with 25% of the shares subject to the option vesting on March 5, 2021 and the remaining 75% of the shares subject to the option vesting in 36 equal monthly installments thereafter.
F2: Each restricted stock unit represents a contingent right to receive one share of Spring Bank Pharmaceuticals, Inc. common stock.
F3: The restricted stock units will vest in two installments. Fifty percent will vest on March 5, 2021 and the remaining fifty percent will vest on December 31, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 03, 2024 Filed Jan 5, 2024 16:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantRestricted Stock Units · Derivative | 100,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-002430 · ownership.xml · derivative · entry 1 Freve Jonathan · CIK 0001664466 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires not disclosed F1 · derivative.exercise_date: Each restricted stock unit represents the right to receive, at settlement, one share of common stock of Galecto, Inc. One-third of the restricted stock units subject to the award will vest on January 3, 2025 and the remaining restricted stock units will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date. F1 · derivative.expiration_date: Each restricted stock unit represents the right to receive, at settlement, one share of common stock of Galecto, Inc. One-third of the restricted stock units subject to the award will vest on January 3, 2025 and the remaining restricted stock units will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date. Read SEC document |
| January 04, 2023 Filed Jan 5, 2023 16:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantStock Option (right to buy) · Derivative | 115,000 | $0.00 Strike: $1.21 | $0.00 |
DisclosureSEC source: 0001209191-23-001756 · doc4.xml · derivative · entry 1 Freve Jonathan · CIK 0001664466 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 115,000 shares Expires 2033-01-03 F1 · derivative.exercise_date: 25% of the shares subject to such option vested and became exercisable on January 4, 2024 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 17:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantStock Option (right to buy) · Derivative | 118,750 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0001209191-22-002211 · doc4.xml · derivative · entry 1 Freve Jonathan · CIK 0001664466 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,750 Underlying: Common Stock · 118,750 shares Expires 2032-01-03 F1 · derivative.exercise_date: 25% of the shares subject to such option vested and became exercisable on January 4, 2023 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| December 03, 2021 Filed Dec 6, 2021 08:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | PurchaseCommon Stock | 4,000 | $2.49 | $9,960.00 |
DisclosureSEC source: 0001209191-21-068027 · doc4.xml · nonDerivative · entry 1 Freve Jonathan · CIK 0001664466 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Read SEC document |
| November 08, 2021 Filed Nov 9, 2021 08:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | PurchaseCommon Stock | 3,000 | $3.40 | $10,200.00 |
DisclosureSEC source: 0001209191-21-063523 · doc4.xml · nonDerivative · entry 1 Freve Jonathan · CIK 0001664466 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Read SEC document |
| August 18, 2021 Filed Aug 19, 2021 16:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | PurchaseCommon Stock | 3,000 | $3.92 | $11,760.00 |
DisclosureSEC source: 0001209191-21-052512 · doc4.xml · nonDerivative · entry 1 Freve Jonathan · CIK 0001664466 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| June 23, 2021 Filed Jun 23, 2021 16:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | PurchaseCommon Stock | 2,000 | $4.74 | $9,480.00 |
DisclosureSEC source: 0001209191-21-042719 · doc4.xml · nonDerivative · entry 1 Freve Jonathan · CIK 0001664466 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 16:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantStock Option (right to buy) · Derivative | 95,000 | $0.00 Strike: $13.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002474 · doc4.xml · derivative · entry 1 Freve Jonathan · CIK 0001664466 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2031-01-05 F1 · derivative.exercise_date: 25% of the shares subject to such option vested and became exercisable on January 5, 2022 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| March 05, 2020 Filed Mar 9, 2020 16:10 UTC | F-star Therapeutics, Inc. SBPH · Entity 115726 | GrantRestricted Stock Units · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-017230 · doc4.xml · derivative · entry 2 Freve Jonathan · CIK 0001664466 · CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Spring Bank Pharmaceuticals, Inc. common stock. F3 · derivative.exercise_date: The restricted stock units will vest in two installments. Fifty percent will vest on March 5, 2021 and the remaining fifty percent will vest on December 31, 2021. F3 · derivative.expiration_date: The restricted stock units will vest in two installments. Fifty percent will vest on March 5, 2021 and the remaining fifty percent will vest on December 31, 2021. Read SEC document |
| March 05, 2020 Filed Mar 9, 2020 16:10 UTC | F-star Therapeutics, Inc. SBPH · Entity 115726 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001209191-20-017230 · doc4.xml · derivative · entry 1 Freve Jonathan · CIK 0001664466 · CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-03-04 F1 · derivative.exercise_date: This option was granted on March 5, 2020, with 25% of the shares subject to the option vesting on March 5, 2021 and the remaining 75% of the shares subject to the option vesting in 36 equal monthly installments thereafter. Read SEC document |
| November 14, 2019 Filed Nov 14, 2019 16:08 UTC | F-star Therapeutics, Inc. SBPH · Entity 115726 | PurchaseCommon Stock | 5,000 | $3.04 | $15,200.00 |
DisclosureSEC source: 0001209191-19-056558 · doc4.xml · nonDerivative · entry 1 Freve Jonathan · CIK 0001664466 · CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,482 Read SEC document |
| May 29, 2019 Filed May 29, 2019 10:16 UTC | F-star Therapeutics, Inc. SBPH · Entity 115726 | PurchaseCommon Stock | 5,000 | $5.40 | $27,000.00 |
DisclosureSEC source: 0001209191-19-033132 · doc4.xml · nonDerivative · entry 1 Freve Jonathan · CIK 0001664466 · CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,482 Read SEC document |
| January 24, 2019 Filed Jan 25, 2019 20:44 UTC | F-star Therapeutics, Inc. SBPH · Entity 115726 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $10.35 | $0.00 |
DisclosureSEC source: 0001209191-19-005451 · doc4.xml · derivative · entry 1 Freve Jonathan · CIK 0001664466 · CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-01-24 F1 · derivative.exercise_date: This option was granted on January 24, 2019, with 25% of the shares subject to the option vesting on January 24, 2020 and the remaining 75% of the shares subject to the option vesting in 36 equal monthly installments thereafter. Read SEC document |
| January 16, 2018 Filed Jan 17, 2018 16:05 UTC | F-star Therapeutics, Inc. SBPH · Entity 115726 | GrantStock Option (Right to Buy) · Derivative | 27,000 | $0.00 Strike: $12.10 | $0.00 |
DisclosureSEC source: 0001209191-18-003920 · doc4.xml · derivative · entry 1 Freve Jonathan · CIK 0001664466 · CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2028-01-16 F1 · derivative.exercise_date: This option was granted on January 16, 2018, with 25% of the shares subject to the option vesting on January 16, 2019 and the remaining 75% of the shares subject to the option vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 09, 2017 Filed Feb 10, 2017 16:24 UTC | F-star Therapeutics, Inc. SBPH · Entity 115726 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $7.66 | $0.00 |
DisclosureSEC source: 0001209191-17-009541 · doc4.xml · derivative · entry 1 Freve Jonathan · CIK 0001664466 · CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-02-09 F1 · derivative.exercise_date: This option was granted on February 9, 2017, with 25% of the shares subject to the option vesting on January 1, 2018 and the remaining 75% of the shares subject to the option vesting in 36 equal monthly installments thereafter. Read SEC document |
| November 23, 2016 Filed Nov 23, 2016 16:02 UTC | F-star Therapeutics, Inc. SBPH · Entity 115726 | GrantWarrant (right to buy) · Derivative | 5,482 | $0.00 Strike: $10.79 | $0.00 |
DisclosureSEC source: 0000899243-16-034299 · doc4.xml · derivative · entry 2 Freve Jonathan · CIK 0001664466 · Director · CFO, Treasurer & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,482 Underlying: Common Stock · 5,482 shares Expires 2021-11-23 Read SEC document |
| November 23, 2016 Filed Nov 23, 2016 16:02 UTC | F-star Therapeutics, Inc. SBPH · Entity 115726 | GrantCommon Stock | 5,482 | $9.12 | $49,995.84 |
DisclosureSEC source: 0000899243-16-034299 · doc4.xml · nonDerivative · entry 1 Freve Jonathan · CIK 0001664466 · Director · CFO, Treasurer & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,482 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.